Marcellin 2013b

Methods	Randomised clinical trial
Participants	351 participants Countries: France, Germany, Poland, and USA Inclusion criteria: treatment‐naive non‐cirrhotic genotype 1 infected HCV participants Exclusion criteria: not described
Interventions	Experimental group: GS‐9451 (200 mg) once daily (those who achieved an extended very rapid virological response (defined as HCV RNA < LLOQ at Weeks 2 and 4 that remained undetectable through week 8) were randomised to stop treatment at either Week 12 or Week 24) Control group: no intervention Co‐intervention: GS‐5885 (30mg once a day) + peg (180 mg/week) + RBV (1000 mg–1200 mg/day)
Outcomes	Adverse events, SVR
Notes	We emailed Marcellin and colleagues on 27 April 2016 for additional information but reply not received yet.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Not described
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not described
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Not described
Selective reporting (reporting bias)	Unclear risk	Safety assessment was not properly described (NCT01356160)
Vested‐interest bias	Unclear risk	Not described
Other bias	Low risk	The trial appeared to be free of other components that could put it at risk of bias